Avita Medical, Inc. insider trading
Every open-market purchase and sale by Avita Medical, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Avita Medical, Inc.’s insiders pay?
From July 21, 2020 to June 10, 2026, 9 insiders reported 21 open-market purchases and 9 sales not made under a pre-set plan in Avita Medical, Inc. Twelve months after each purchase was reported, the shares were −55.8% against the S&P 500 on average (median −62.5%), over 14 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −33.5% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on July 22, 2020 into $2,592 by November 2, 2026, −19.4% a year. It held shares 85% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $21,903 (+13.3% a year), and held throughout $25,194 (+15.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| O'toole David D | CFO | 11 | −54.9% (10) | 0% | 0 | — | February 23, 2026 |
| Perry Michael S | Chief Executive Officer | 0 | — | — | 6 | −28.9% (6) | November 22, 2022 |
| Mcnamara Robert | Director | 4 | −63.6% (2) | 0% | 0 | — | August 29, 2025 |
| Woody Joseph Fralin | Director | 4 | — | — | 0 | — | June 10, 2026 |
| Cook Jeremy Curnock | Director | 0 | — | — | 1 | −30.6% (1) | December 14, 2023 |
| Corbett James | CEO | 0 | — | — | 1 | −32.4% (1) | December 27, 2023 |
| Crowe Suzanne | Director | 1 | −54.3% (1) | 0% | 0 | — | September 21, 2021 |
| Mcintyre David | Chief Financial Officer | 1 | −51.2% (1) | 0% | 0 | — | July 21, 2020 |
| Shiroma Donna | General Counsel | 0 | — | — | 1 | −65.5% (1) | September 8, 2023 |
When several insiders traded Avita Medical, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Avita Medical, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −61.5% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| February 28, 2025 | 2 buying | −37.7% | −61.5% | −63.0% |